Cortexolone 17α-valerate-21-propionate is a highly potent oral Androgen Receptor (AR) and Glucocorticoid Receptor (GR) antagonist for the treatment of solid tumors. It has the potential for first- and second-line therapy in pancreatic and colon cancers. Regulatory Toxicology studies show that oral dosing is safe and well-tolerated.
Cosmo is partnering with ICON PLC, one of the world’s largest contract research organizations (CRO), which provides specialized and experienced services for the management of oncology clinical trials.
A Phase I study in patients with advanced refractory solid tumors (Pancreas, Colon, Prostate) (NCT 03863145) has begun. As of July 2022 several clinical sites in the U.S. have been activated and patient dosing has commenced.
It has one patent granted in the U.S.A., Europe, Australia, Mexico, Korea, and Hong Kong.